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ORIGINAL RESEARCH
Variation of T2 Relaxation Times
in Pediatric Brain Tumors and Their
Effect on Metabolite Quantification
Dominic Carlin, PhD ,1,2† Ben Babourina-Brooks, PhD,1,2† Nigel P. Davies, PhD,2,3
Martin Wilson, PhD,2,4 and Andrew C. Peet, MBBS, PhD1,2*
Background: Metabolite concentrations are fundamental biomarkers of disease and prognosis. Magnetic resonance
spectroscopy (MRS) is a noninvasive method for measuring metabolite concentrations; however, quantitation is affected
by T2 relaxation.
Purpose: To estimate T2 relaxation times in pediatric brain tumors and assess how variation in T2 relaxation affects
metabolite quantification.
Study Type: Retrospective.
Population: Twenty-seven pediatric brain tumor patients (n5 17 pilocytic astrocytoma and n5 10 medulloblastoma) and
24 age-matched normal controls.
Field Strength/Sequence: Short- (30 msec) and long-echo (135 msec) single-voxel MRS acquired at 1.5T.
Assessment: T2 relaxation times were estimated by fitting signal amplitudes at two echo times to a monoexponential
decay function and were used to correct metabolite concentration estimates for relaxation effects.
Statistical Tests: One-way analysis of variance (ANOVA) on ranks were used to analyze the mean T2 relaxation times
and metabolite concentrations for each tissue group and paired Mann–Whitney U-tests were performed.
Results: The mean T2 relaxation of water was measured as 181 msec, 123 msec, 90 msec, and 86 msec in pilocytic
astrocytomas, medulloblastomas, basal ganglia, and white matter, respectively. The T2 of water was significantly longer
in both tumor groups than normal brain (P< 0.001) and in pilocytic astrocytomas compared with medulloblastomas
(P<0.01). The choline T2 relaxation time was significantly longer in medulloblastomas compared with pilocytic astrocy-
tomas (P< 0.05), while the T2 relaxation time of NAA was significantly shorter in pilocytic astrocytomas compared with
normal brain (P< 0.001). Overall, the metabolite concentrations were underestimated by 22% when default T2 values
were used compared with case-specific T2 values at short echo time. The difference was reduced to 4% when individu-
ally measured water T2s were used.
Data Conclusion: Differences exist in water and metabolite T2 relaxation times for pediatric brain tumors, which lead to
significant underestimation of metabolite concentrations when using default water T2 relaxation times.
Level of Evidence: 3
Technical Efficacy: Stage 2
J. MAGN. RESON. IMAGING 2018;00:000–000.
Brain tumors are the most common solid tumors in chil-dren and a significant cause of morbidity and mortality.
1H magnetic resonance spectroscopy (MRS) provides a non-
invasive means of profiling the chemical composition of
brain tumors, providing prognostic and diagnostic bio-
markers that can be used for tumor classification1,2 and for
monitoring treatment response.3 As quantitative metabolite
biomarkers start to be proposed for clinical decision-making
in individual patients,4,5 accurate measurement becomes of
increasing importance.
MRS is typically implemented clinically by adhering
to an agreed protocol and comparing the results to those
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obtained using the same protocol. This strategy is known to
be reproducible when a single scanner is involved6 and a
reasonable comparison can also be made between different
scanners and centers providing the protocol is adhered to.2
While metabolite levels can be reported as ratios, quantifica-
tion is typically performed by fitting to a set of metabolite
basis functions and concentrations are calculated with refer-
ence to an unsuppressed water signal.7
Popular analysis packages, LCModel8 and TAR-
QUIN,9 are often used for metabolite quantification, assum-
ing T2 relaxation times typical of normal brain in their
calculations. However, relaxation times are sensitive to
microenvironment and have been shown to change with
pathology.10–13 In the previous major studies of brain
tumors using MRS, further correction for the differences in
T2 relaxation between brain tumors and healthy brain has
not been performed and the effects of T2 relaxation varia-
tion have been assumed to be small at short echo time
(TE).1,2,14
The use of longer TEs for metabolite quantification
has been proposed recently12,15–17; however, T2 relaxation
times are known to have a significant effect on concentra-
tion determination at long TEs18 and correction for T2
relaxation has been shown to have a significant effect on
metabolite ratios at 3T.13 Accurate water and metabolite T2
relaxation times are therefore likely to be required for reli-
able metabolite quantification. With the emergence of vari-
ous acquisition protocols, it is becoming increasingly
important to explore the effects of relaxation on quantifica-
tion at various TEs.
In a recent multicenter study of pediatric brain
tumors,2 reporting concentrations measured at both short-
and long-TE, a large difference was seen between the con-
centrations measured at the two echo times. Although a
recent study has examined the effect of using long-TEs for
quantification using LCModel,18 the influence of T2 relaxa-
tion times on brain tumor quantification at short-TE was
not formally assessed.
While previous studies of adult brain tumors have
shown significant differences in both water and metabolite
T2 relaxation times,
10–13 T2 relaxation in childhood brain
tumors has not been extensively studied to date. Investiga-
tion of relaxation times in the pediatric population is of par-
ticular importance, as metabolite T2 relaxation times in
normal brain have been shown to change with age.19 In
addition, for brain tumors, specific studies in children are
required since the tumors are histologically and biologically
different from their adult counterparts.20,21 Pilocytic astro-
cytomas and medulloblastomas are particularly common in
children but are rare in adults.22,23
Measuring T2 formally is challenging since acquisition
protocols require multiple echo times and this leads to long
acquisition times. However, protocols using two echo times
have been implemented clinically and offer the potential to
estimate the T2 values of metabolites and water while keep-
ing acquisition times within reasonable timeframes.2,10 This
issue is particularly pertinent to the study of children, where
long scans are poorly tolerated.
In this study, metabolite and water T2 relaxation times
in apparently normal brain and childhood brain tumors
were retrospectively calculated from data collected at both
short- and long-TE with the aim of establishing how the
relaxation properties of major metabolites vary and the
effect this has on metabolite quantification.
Materials and Methods
Patients
Two cohorts were retrospectively selected from patients where
single-voxel MRS had been performed prior to treatment between
September 2006 and July 2011. The first cohort consisted of 27
children with brain tumors. This tumor group was comprised of
10 medulloblastomas (six male and four female, mean age 6.1
years) and 17 pilocytic astrocytomas (nine male and eight female,
mean age 7.4 years).
Comparison was made with a second cohort consisting of 24
age-matched children (18 male and 6 female, mean age 6.4 years).
These children had MRI and MRS as part of an investigation for a
suspected metabolic disorder. Metabolic disorders were subse-
quently ruled out for these children and all children had normal-
appearing MRI and MRS. All patients were under 16 years of age
and contemporaneous informed parental consent and research
ethics approval was obtained that covered future analyses.
MRS Acquisition
MRS was acquired using a Siemens Symphony Magnetom NUM4
1.5T scanner (Siemens Healthcare, Erlangen, Germany) following
conventional imaging. The standard imaging set of T1-weighted,
T2-weighted, and T1-weighted images postcontrast administration
was used to delineate the tumor margins. Cubic voxels of side
length 1.5 cm or 2 cm were placed entirely within the solid compo-
nent of the tumor, avoiding any cyst or necrosis, and point-
resolved spectroscopy (PRESS) was performed. Cubic voxels of
side length 2 cm were placed in the basal ganglia and parietal white
matter in the cohort with normal-appearing MRI and MRS.
Water-suppressed data were acquired with 128 repetitions from the
larger voxels and 256 repetitions from the smaller ones. For all
MRS acquisitions, a relaxation time (TR) time of 1500 msec was
used and data were acquired at both short (30 msec) and long
(135 msec) TE from the same voxel. Water-unsuppressed MRS
data were also acquired with four repetitions as a concentration ref-
erence at both TEs.
Processing and Analysis
Raw spectroscopy data were automatically processed using TAR-
QUIN v. 4.3.8.9 TARQUIN models experimental data as a linear
combination of simulated basis signals. To extract metabolite con-
centrations, the fitted signal amplitudes a^ are scaled by two factors:
Watt and Wconc.
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The Watt parameter accounts for the reduction of the water
signal relative to metabolite signals due to differences in T2 relaxa-
tion at a given TE and is defined as Watt5 [exp(–TE/T2water) /
exp(–TE/T2metabolite)]. This parameter is used to adjust the metab-
olite concentrations to be independent of TE and will give the cor-
rect value if T2water and T2metabolite are known accurately. Wconc
denotes the assumed water concentration for a given tissue type
and is used to scale a^ to the amplitude of the unsuppressed water
signal. Wconc and Watt are assumed as 35,880mM and 0.7, respec-
tively, by TARQUIN as the default.
Tumor spectra were referenced to the total choline signal to
account for frequency drift, while normal brain spectra were referenced
to a combination of total choline-creatine-NAA-lipids. The following
metabolite, lipid, and macromolecule signals were included in the basis
set: alanine (Ala), aspartate (Asp), c-aminobutyric acid (GABA), glycer-
ophosphocholine (GPC), glucose (Glc), glutamine (Gln), glutathione
(Glth), glutamate (Glu), glycine (Gly), myo-Inositol (mI), lactate (Lac),
N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), phos-
phocholine (PCh), phosphocreatine (PCr), scyllo-Inositol (Scy), taurine
(Tau), lipids at 0.9, 1.3 (a1b), and 2.0 ppm andmacromolecules at 0.9,
1.2, 1.4, 1.7, and 2.0 ppm. Due to significant spectral overlap at 1.5T,
the following metabolites were combined in the subsequent analysis:
Gln1Glu5Glx; NAA1NAAG5 tNAA; Cr1PCr5 tCr and
GPC1PCh5 tCho.
T2 MEASUREMENT. T2 relaxation times were estimated by fit-
ting TARQUIN estimates of signal amplitude a^9 for each metabo-
lite from the two echo times to a monoexponential function. Two
expert spectroscopists (D.C. and B.B.B., 4 years of experience
each) assessed the presence of tNAA, tCho, and tCr in short- and
long-TE MRS independently. T2 relaxation times were estimated
for the cases where both assessors agreed that the metabolites could
be identified at both TEs from visual inspection.
CONCENTRATION CALCULATION. To assess the importance of
accurate T2 relaxation times for metabolite quantification, we com-
pared metabolite concentrations corrected using combinations of
the measured T2 values and using literature T2 values. The follow-
ing terms are used for the various methods of obtaining the T2 val-
ues. Tissue type refers to pilocytic astrocytoma, medulloblastoma,
or normal brain.
Individual water (IW) correction uses the T2 relaxation time
of water measured as part of the MRS acquisition for that case.
Average metabolite (AM) correction uses the average T2
relaxation time for the metabolites obtained from the cases in the
study with the same tissue type for tNAA, tCho, and Cr and a
metabolite T2 of 400 msec for all other metabolites.
For literature T2 correction, water T2s were assumed to be
86 msec for normal brain.24 Metabolite T2s of 368.8, 205.3, and
265.4 msec were used for tNAA, tCr, and tCho, respectively, in
healthy brain.25 As T2 relaxation has been relatively unexplored in
childhood pilocytic astrocytoma and medulloblastoma, literature
correction for our brain tumor cohorts used published T2 values
for adult gliomas.11 The water T2 relaxation times were taken to
be 174.5 msec in both brain tumor types. The T2 values for
tNAA, tCr, and tCr were 227.5, 196.3, and 275.3 msec,
respectively.
The term default is used for concentrations estimated using
TARQUIN’s default Watt value of 0.7. This value is based on
TE5 30 msec data collected in adults at 1.5T and assumes T2
relaxation times typical of white matter.
Metabolite concentrations quantified at short-TE were cor-
rected for relaxation effects by calculating case-specific Watt values
using AM and IW T2 values, for which we use the shorthand nota-
tion (AM, IW). These values are assumed to be the best estimates
of the metabolite values and all other methods are compared
against these with the root mean square (rms) differences being
reported.
Quality Control
MRS data were required to have a water linewidth (full-width-at-
half maximum, FWHM) <15Hz and signal-to-noise ratio (SNR)
4. Spectra were reviewed for quality by two expert spectroscop-
ists. Short- and long-TE spectra were assessed to identify metabo-
lites present at both echo times for inclusion in the T2 analysis.
Statistics
One-way analysis of variance (ANOVA) on ranks tests were used
to analyze the T2 relaxation times and metabolite concentrations
for the four tissue groups and paired Mann–Whitney U-tests were
performed. Statistical significance was declared for P< 0.05.
Results
After quality control, 11 pilocytic astrocytoma, 10 medullo-
blastoma, 15 white matter, and 16 basal ganglia spectra
were used in the analysis. A total of 45 tNAA (10 pilocytic
astrocytomas, 5 medulloblastoma, 14 white matter, and 16
basal ganglia), 43 tCr (8 pilocytic astrocytomas, 9 medullo-
blastoma, 10 white matter, and 16 basal ganglia), and 49
tCho (11 pilocytic astrocytomas, 9 medulloblastoma, 15
white matter, and 14 basal ganglia) were included in the T2
analysis. Figure 1 shows examples pilocytic astrocytoma and
medulloblastoma spectra. Figure 2 shows example basal gan-
glia and white matter spectra.
T2 Results
T2 values for metabolites and water are represented in Fig. 3,
with the values given in Table 1. tCho was significantly longer
in medulloblastomas compared with pilocytic astrocytoma
(P5 0.04) and compared with white matter (P< 0.001) and
basal ganglia (P< 0.001). The T2 relaxation time of tNAA
was significantly shorter in pilocytic astrocytomas compared
with white matter (P< 0.001) and basal ganglia (P< 0.001).
The T2 TRs of tissue water in pilocytic astrocytomas
1816 35 msec and medulloblastomas 1236 45 msec were
found to be significantly longer than in basal ganglia, 906 9
msec, and white matter 866 8 msec (P5 1026 in all cases).
The T2 TR of water was significantly longer in pilocytic astro-
cytomas than in medulloblastomas (P5 0.001).
The mean Watt values, calculated using the mean tissue
water and metabolite T2 TRs, were 0.95, 0.85, and 0.80 for
pilocytic astrocytomas, medulloblastomas, and normal brain,
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respectively, at TE5 30 msec. There was no correlation
between T2 TRs and age in normal brain for water or any
of the metabolites.
Effect of T2 Correction on Metabolite
Concentrations
Metabolite concentrations were measured and adjusted using
various combinations of T2 values: default T2 values; literature
T2 values; a value of 400 msec for metabolite T2 and individu-
ally measured water T2 (IW); average metabolite T2 (AM) and
IW. A comparison of mean concentrations for tNAA, tCho,
and tCr determined using these protocols is shown in Fig. 4.
Concentrations corrected using the default protocol
were significantly underestimated compared with those esti-
mated using the AM, IW correction regime (P< 0.05).
However, concentrations estimated using different metabo-
lite T2 values were comparable, providing the same water
T2 value was used for correction. When averaged over all
metabolites and all tissue types, the mean short TE MRS
metabolite concentrations calculated using the default T2
TRs were significantly underestimated by 22% compared
with the best estimate mean concentrations determined
using the IW and AM TRs (P< 0.001). Metabolite concen-
trations were underestimated by 4% when a metabolite T2
of 400 msec and IW T2 were used.
The rms error of metabolite concentrations estimated
using (default T2) and (400 msec, IW) relaxation times
compared with those using (AM, IW) relaxation times are
presented in Table 2 for each tissue type. The rms errors
observed at short-TE were significantly smaller than those at
long-TE when observing the patient cohort as a whole
(24% vs. 58% for default T2s vs. AM, IW, P <0.001).
Mean Metabolite Concentrations Corrected for T2
Relaxation Times for Each Tissue Type
Mean metabolite concentrations for the different tissue types
calculated using an IW, AM T2 corrected protocol are pre-
sented in Table 3. The concentrations of tNAA (P< 0.001),
tCr (P< 0.001), and Glx (P< 0.001) were significantly
lower in tumors compared with normal brain, while Lac
(P5 1024) was significantly higher in tumors. The concen-
tration of tCho (P< 0.001), Tau (P< 0.01), Gly
(P< 0.01), and tCr (P< 0.05) were significantly higher in
medulloblastomas compared with pilocytic astrocytomas.
FIGURE 1: Example spectra from (a) pilocytic astrocytoma astrocytoma and (b) medulloblastoma at short- and long-TE with TAR-
QUIN fits (red) and fit residuals shown beneath the spectra.
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Discussion
In this study, T2 relaxation times of metabolites and water
were estimated in childhood brain tumors and metabolite
concentrations corrected for relaxation effects are reported.
The importance of T2 relaxation times for quantification
was also assessed.
In previous major studies of metabolite concentrations
in brain tumors,1,2,14,26 no correction for the differences in
T2 relaxation times of brain tumors and healthy brain was
performed. A water attenuation factor of 0.7 is applied to
the data by default in LCModel and TARQUIN. This value
is calculated using data collected at 1.5T in healthy adult
brain assuming a TE of 30 msec and is not suitable for
quantification of long-TE data. In the current study, con-
centrations measured without further correction for the dif-
ferences in relaxation were typically underestimated by
22% at short-TE.
While there are differences between the concentrations
corrected for water and metabolite T2 versus those corrected
using the default T2 values, the main features in the metabo-
lite profiles reported for medulloblastomas and pilocytic
astrocytomas in children have been substantiated.1,2,14 While
previous studies have assessed the influence of T2 relaxation
on metabolite ratios13 and quantification at long-TE,18 this
study assessed the variation in relaxation time in pediatric
brain tumors and normal brain and the effect on metabolite
quantification. The relative importance of water and metabo-
lite T2 relaxation times was also assessed. The T2 relaxation
time of tissue water was found to have a greater effect on
concentration measurements than the T2 relaxation time of
metabolites. An additional multi-TE acquisition to measure
the T2 of water can be implemented with a scan time of less
than a minute, and is recommended to improve the accuracy
of metabolite quantification. This may be particularly perti-
nent if using quantitative MRS to assess treatment response,
as tumor water T2 is known to reduce following treat-
ment.27–29 However, if water T2 values for individual cases
are not available, then the mean values for the relevant tissue
type would be preferable to default values.
At long-TE, the rms percentage differences from con-
centrations corrected for both IW and AM T2 relaxation
were larger than at short-TE, suggesting that accurate
metabolite T2 values are of more importance at long echo
times than at short. This is as expected, since signal losses
FIGURE 2: Example spectra from (a) basal ganglia and (b) white matter at short- and long-TE with TARQUIN fits (red) and fit resid-
uals shown beneath the spectra.
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due to T2 relaxation effects increase with echo time and
inaccurate T2 estimation will lead to greater errors at longer
echo times. Since we detected no significant differences in
the T2 measurements between tissue types for the majority
of metabolites, T2 values determined from normal brain
could reasonably be used in determining concentrations for
tumors. More accurate values are likely to be obtained if
metabolite-specific T2s are used, although this is somewhat
more challenging to implement.
A number of studies have reported T2 relaxation times
of adult brain tumors at 1.510,11 and 3T13,30; however,
relaxation times in pediatric brain tumors have been rela-
tively unexplored. Consistent with observations of prolonged
water T2 in adult brain tumors, the T2 relaxation time of
water was found to be significantly longer in tumors than
normal brain and in pilocytic astrocytomas compared with
medulloblastomas. The long water T2 in brain tumors is
consistent with the high signal seen on T2-weighted imaging
compared with gray matter and corresponds to the high
water content, especially in pilocytic astrocytomas. For abso-
lute metabolite quantification, differences in water content
should be accounted for. No correction was made for varia-
tions of water tissue content, in keeping with previous stud-
ies of brain tumors, and it is not known what error this will
introduce on concentration measurements. However, voxels
were placed entirely within the solid component of the
tumor to exclude all cystic components. Tissue water con-
tent is rarely determined in clinical studies and its effect
should be the subject of a future study.
The T2 of tCho was found to be significantly longer
in medulloblastomas compared with pilocytic astrocytomas.
The reason for the long T2 of tCho in medulloblastoma is
uncertain. However, the resonance at 3.20 ppm is composed
mainly of PCh in medulloblastomas and GPC in glio-
mas.31,32 A longer PCh T2 would be consistent with its
lower molecular weight relative to GPC. The significantly
lower T2 of tNAA in pilocytic astrocytomas compared with
normal brain would be consistent with some of the signal
around 2 ppm being from a macromolecular component,
although it is not sufficiently low for this to explain all the
signal.33
A limitation of this retrospective study is that only two
TEs were used to evaluate T2 relaxation times. The relatively
short range of TE values used and the bias due to exclusion of
cases where the signal could not be accurately fitted at the lon-
ger echo time may have led to an overestimation of metabolite
T2 values.
34 Lac could not be reliably quantified at short-TE
and quantification of lipids and macromolecules was not pos-
sible at long-TE. For optimal evaluation of the relaxation
times of coupled metabolites, appropriate TE values should be
determined following evaluation of the J-evolution of metabo-
lite signals, as overlap of chemically inequivalent species will
have an effect on the apparent T2 of MRS peaks.
35 However,
the optimal TE values vary between metabolites and using
additional TEs is prohibitively time-consuming for routine
tumor evaluation in a clinical environment. If a dual echo
FIGURE 3: Mean (standard error) T2s of tNAA, tCho, tCr, and
water for pilocytic astrocytomas, medulloblastomas, basal gan-
glia, and normal white matter. *P<0.05, **P<0.001.
TABLE 1. Estimated Metabolite T2 Relaxation Times (msec) in Pilocytic Astrocytoma, Medulloblastoma, Basal
Ganglia (BG), and White Matter (WM)
T2 relaxation time (msec)
Pilocytic astrocytomas Medulloblastomas BG WM
Mean SD n Mean SD n Mean SD n Mean D n
tNAA 1916 56 10 3336 124 5 4366 140 16 4236 113 14
tCho 3726 176 11 5876 143 9 3446 122 14 3136 154 15
tCr 2176 65 8 3056 51 9 2256 78 16 2376 72 10
Water 1816 35 11 1236 45 10 906 9 16 866 8 15
Journal of Magnetic Resonance Imaging
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time acquisition is to be used, we do not currently know the
optimum pair of values, but a shorter second echo time than
used in this study could allow for more cases to be assessed
due to the higher SNR at shorter-TEs. Estimation of water T2
values requires a much shorter acquisition due to its high sig-
nal intensity and could readily be included as part of the rou-
tine protocol.
While we have investigated the effects of T2 relaxation on
metabolite determination, no attempt was made to correct for
T1 saturation effects. In clinical studies, a TR of 1500 msec is
typically used in pediatric single-voxel spectroscopy studies at
1.5T.1,2,14 This relative consistency should provide compara-
bility of data between studies. A previous study of relaxation
effects in adult brain tumors found no significant differences in
the T1 between metabolites or between tissue types,
10 implying
that metabolite values may be comparable even if a different
TR is used.
Our study design has a number of limitations. First, the
study was conducted retrospectively and the number of
patients included in the analysis was relatively small. Second,
we used AM, IW concentration estimates as our standard, as
the precise metabolite concentrations are unknown. Although
our method will reduce errors introduced by misestimation
of metabolite relaxation times, this choice is somewhat arbi-
trary. Finally, measuring the T2 relaxation times postcontrast
may have introduced some errors into our T2 estimates. Our
T2 estimates may therefore be underestimated by as much as
16%; however, preclinical evidence suggests that there is little
difference in the T2 relaxation times at different moments of
the contrast washout.36
In conclusion, T2 relaxation times of water and metab-
olites vary between tissue types in children. Using a short
echo time and correcting for T2 effects with the best values
available, preferably including case-specific water T2 values,
will reduce inaccuracies due to T2 variability. T2 values
themselves are a measure of molecular environment and
may provide an additional means of investigating and char-
acterizing tissue.
FIGURE 4: Mean6 standard error metabolite concentrations
(mM) in (a) pilocytic astrocytoma, (b) medulloblastoma, and (c)
normal brain estimated at short-TE. Metabolite concentrations
are corrected for relaxation effects using either default TAR-
QUIN relaxation correction; literature T2 values; a metabolite
T2 of 400 msec and a patient measured water (IW) T2; or the
average metabolite (AM) T2 for that tissue type and IW T2.
*P<0.05, **P<0.01.
TABLE 2. Root Mean Square Percentage Difference
Between Metabolite Concentrations Corrected Using
Different Combinations of T2 Relaxation Times (see
Materials and Methods) Compared to the Corrected





Short TE singlets 31.1 5.5 6.0




Short TE singlets 17.6 16.1 1.9




Short TE singlets 13.9 3.8 3.3
Long TE singlets 73.8 16.9 14.8
A, average; I, individual; M, metabolite; W, water.
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